VEGFA and cancer: Three anti-angiogenic drugs, bevacizumab (Avastin®), sunitinib malate (Sutent®, SU11248) and sorafenib (Nexavar®, BAY 43-9006), inhibiting VEGF signaling by either blocking VEGF ligands or VEGFRs, have been approved by the United States Food and Drug Administration for cancer treatment [34].